GH 9001
Latest Information Update: 25 May 2004
Price :
$50 *
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 13 May 2004 Discontinued - Phase-I for Thrombosis in Canada (IV)
- 13 May 2004 Discontinued - Phase-I for Thrombosis in Canada (SC)
- 13 May 2004 Discontinued - Phase-I for Thrombosis in United Kingdom (IV)